Cardiovascular toxicity associated with angiogenesis inhibitors: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System database from 2014 to 2021

BACKGROUND: The profiles of cardiovascular toxicity associated with angiogenesis inhibitors, including intravenous monoclonal antibodies (mAbs) and oral tyrosine kinase inhibitors (TKIs), targeting vascular endothelial growth factor (VEGF) remain poorly elucidated in real-world settings. This pharma...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, YanFeng, Cui, Chanjuan, Ren, Xiayang, Dong, Xinran, Cui, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606330/
https://www.ncbi.nlm.nih.gov/pubmed/36312283
http://dx.doi.org/10.3389/fcvm.2022.988013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606330/
https://www.ncbi.nlm.nih.gov/pubmed/36312283
http://dx.doi.org/10.3389/fcvm.2022.988013

Ejemplares similares